RSS Feed from EMA on New Human Medicines
- Human medicines European public assessment report (EPAR): Colchicine Agepha Pharma, colchicine, Status: Opinion
- Human medicines European public assessment report (EPAR): Etcamah, camizestrant, Status: Opinion
- Human medicines European public assessment report (EPAR): Vislyfa, ranibizumab, Status: Opinion
- Human medicines European public assessment report (EPAR): Vijoice, alpelisib, Status: Opinion
- Human medicines European public assessment report (EPAR): Liraglutide STADA, liraglutide, Status: Opinion
- Human medicines European public assessment report (EPAR): Ablymico, liraglutide, Status: Opinion
- Human medicines European public assessment report (EPAR): Deqtynet, copper (64Cu) oxodotreotide, Status: Opinion
- Human medicines European public assessment report (EPAR): Iloperidone Vanda Pharmaceuticals, iloperidone, Status: Opinion
- EMA, AMA and African regulatory authorities join forces on Ebola outbreak response
- United for Health: EMA in WorldPride 2026
- ETF recommends updating COVID-19 vaccines to target XFG variant
- EU recommendations for 2026/2027 seasonal flu vaccine composition
- Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 19-21 May 2026
MedWatch Safety Alert RSS Feed
- Anesthesia Delivery Systems Recall: GE HealthCare Issues Correction for Certain Carestations due to Risk of Ineffective Ventilation When Used in Volume Control Ventilation (VCV) Mode
- Early Alert: Infant Resuscitation System Issue from GE HealthCare
- Early Alert: Insulin Pump Issue from Insulet
- Haleon Issues Voluntary Nationwide Recall of Gas-X Extra Strength Softgels 125mg, 120 ct. and 72 ct.
- Anesthesia Kit Correction: Becton Dickinson Issues Correction for BD Spinal Trays Containing Bupivacaine Ampules
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication
- 2024 Safety Communications
- Early Alert: Catheter Introducer Kit Issue from Abiomed
- Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
FDA Stay Informed on New Drugs
- Fiscal Year 2026 Generic Drug Science and Research Initiatives Public Workshop - 06/08/2026
- Approved Drugs: Questions and Answers
- Generic Drugs: Questions & Answers
- CDER Leadership Bios
- Over-The-Counter Monograph Drug User Fee Program (OMUFA)
- Generic Drug User Fee Amendments
- What's New Related to Drugs
- Sexual Enhancement and Energy Product Notifications
- Pink Pussycat Brand products may be harmful due to hidden drug ingredients
- Heparin Importation